Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by Javier Zueco Gil
Based on 2 articles published since 2009
(Why 2 articles?)
||||

Between 2009 and 2019, Javier Zueco Gil wrote the following 2 articles about Coronary Artery Disease.
 
+ Citations + Abstracts
1 Article Procedural resources utilization and clinical outcomes with bioresorbable everolimus-eluting scaffolds and Pt-Cr everolimus-eluting stent with resorbable abluminal polymer in clinical practice. A randomized trial. 2017

de la Torre Hernandez, Jose M / Garcia Camarero, Tamara / Lee, Dae-Hyun / Sainz Laso, Fermin / Veiga Fernandez, Gabriela / Pino, Tania / Rubio, Silvia / Legarra, Pablo / Valdivia, Jorge R / Zueco Gil, Javier. ·Hospital Universitario Marques de Valdecilla, Department of Cardiology, Interventional Cardiology Unit, Santander, Spain. ·Catheter Cardiovasc Interv · Pubmed #27807948.

ABSTRACT: OBJECTIVES: We sought to compare the procedural implications of using bioresorbable everolimus-eluting scaffolds (BVS) and Pt-Cr everolimus-eluting stent with abluminal bioabsorbable polymer (Synergy). BACKGROUND: There are important differences in the respective platforms, which could impact on procedural performance, complications and outcomes. METHODS: A prospective, randomized single center study including consecutive patients in stable clinical condition and with lesions amenable to be treated with BVS according to predefined criteria. Patients were randomized to either treatment with BVS or Synergy. All procedural data were collected and 12 months clinical follow up conducted. Primary objectives were fluoroscopy time, median dose-area product, contras agent volumen, and peri-procedural troponin release. RESULTS: A total of 200 patients were included, 100 in BVS group and 100 in Synergy group. No significant differences were observed in baseline clinical and angiographic characteristics. Predilatation (97.6 vs. 25.4%; P < 0.001), postdilatation (64.8 vs. 38.4%: P < 0.01), and use of 2 wires (20.8 vs. 10%; P = 0.02) were more frequent with BVS. The BVS group showed a significant increase in fluoroscopy time (18%), dose-area product (20%), and contrast volume (10%). Post-procedural increase of creatinine was similar and amount of TnI release was significantly higher with BVS but incidence of peri-procedural infarction was comparable. Clinical outcomes at 12 months were similar with definite thrombosis being 1% with BVS and 0% with Synergy. CONCLUSIONS: The use of BVS in comparison with the Synergy stent in a similar lesional setting is associated with a higher use of resources in the procedure, more radiation, and higher TnI release. © 2016 Wiley Periodicals, Inc.

2 Article Clinical impact of intravascular ultrasound guidance in drug-eluting stent implantation for unprotected left main coronary disease: pooled analysis at the patient-level of 4 registries. 2014

de la Torre Hernandez, Jose M / Baz Alonso, José A / Gómez Hospital, Joan A / Alfonso Manterola, Fernando / Garcia Camarero, Tamara / Gimeno de Carlos, Federico / Roura Ferrer, Gerard / Recalde, Angel Sanchez / Martínez-Luengas, Iñigo Lozano / Gomez Lara, Josep / Hernandez Hernandez, Felipe / Pérez-Vizcayno, María J / Cequier Fillat, Angel / Perez de Prado, Armando / Gonzalez-Trevilla, Agustín Albarrán / Jimenez Navarro, Manuel F / Mauri Ferre, Josepa / Fernandez Diaz, Jose A / Pinar Bermudez, Eduardo / Zueco Gil, Javier / Anonymous4770788. ·Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital Marques de Valdecilla, Santander, Spain. Electronic address: he1thj@humv.es. · Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital Meixoeiro, Vigo, Spain. · Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital Bellvitge, Barcelona, Spain. · Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital Clinico San Carlos, Madrid, Spain. · Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital Marques de Valdecilla, Santander, Spain. · Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital de Valladolid, Valladolid, Spain. · Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital La Paz, Madrid, Spain. · Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital Central de Asturias, Oviedo, Spain. · Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital 12 de Octubre, Madrid, Spain. · Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital de Leon, Leon, Spain. · Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital Virgen de la Victoria, Malaga, Spain. · Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital Germans Trias i Pujol, Badalona, Spain. · Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital Puerta de Hierro, Madrid, Spain. · Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital Virgen de la Arrixaca, Murcia, Spain. ·JACC Cardiovasc Interv · Pubmed #24650399.

ABSTRACT: OBJECTIVES: This study sought to investigate the clinical impact of the use of intravascular ultrasound (IVUS) during revascularization of patients with left main coronary artery (LM) disease with drug-eluting stents (DES). BACKGROUND: Whether the use of IVUS during the procedure adds a clinical benefit remains unclear. There is only 1 previous observational study, with relevant limitations, supporting the value of this strategy. METHODS: We performed a patient-level pooled analysis of 4 registries of patients with LM disease treated with DES in Spain. A propensity score-matching method was used to obtain matched pairs of patients with and without IVUS guidance. RESULTS: A total of 1,670 patients were included, and 505 patients (30.2%) underwent DES implantation under IVUS guidance (IVUS group). By means of the matching method, 505 patients without the use of IVUS during revascularization were selected (no-IVUS group). Survival free of cardiac death, myocardial infarction, and target lesion revascularization at 3 years was 88.7% in the IVUS group and 83.6% in the no-IVUS group (p = 0.04) for the overall population, and 90% and 80.7%, respectively (p = 0.03), for the subgroups with distal LM lesions. The incidence of definite and probable thrombosis was significantly lower in the IVUS group (0.6% vs. 2.2%; p = 0.04). Finally, IVUS-guided revascularization was identified as an independent predictor for major adverse events in the overall population (hazard ratio: 0.70, 95% confidence interval: 0.52 to 0.99; p = 0.04) and in the subgroup with distal lesions (hazard ratio: 0.54, 95% confidence interval: 0.34 to 0.90; p = 0.02). CONCLUSIONS: The results of this pooled analysis show an association of IVUS guidance during percutaneous coronary intervention with better outcomes in patients with LM disease undergoing revascularization with DES.